Mechanism Comparison

Both AOD-9604 and HGH Fragment 176-191 are derived from the C-terminal lipolytic domain of human growth hormone and act through a receptor interaction that is structurally and pharmacologically distinct from the canonical two-site GH receptor (GHR) binding mechanism responsible for IGF-1 secretion, linear growth, and hyperglycemia. HGH Fragment 176-191 corresponds to the 16 native C-terminal amino acids of hGH (residues 176–191) and was the foundational compound demonstrating that lipolytic and anabolic activities of GH could be structurally dissociated. Its proposed mechanism involves binding to a distinct adipocyte receptor (not the canonical GHR) that couples to adenylate cyclase, activating cAMP → hormone-sensitive lipase (HSL) → triglyceride hydrolysis while simultaneously suppressing lipogenesis via downregulation of fatty acid synthase (FAS). AOD-9604 (Anti-Obesity Drug 9604) corresponds to residues 177–191 of hGH with an additional N-terminal tyrosine added to stabilise the fragment and improve bioavailability — a pharmaceutical optimization of HGH Fragment 176-191 developed by Metabolic Pharmaceuticals (now Calzada Ltd.). AOD-9604 shares the same downstream adipocyte cAMP/HSL lipolytic mechanism and retains the absence of GHR binding, IGF-1 stimulation, and hyperglycemic effects documented in HGH Fragment 176-191. The structural addition of the N-terminal tyrosine is the key chemical distinction: it increases peptide stability and provides an additional pharmacophore without altering the receptor selectivity profile established in the parent fragment.

Side-by-Side Attributes

Key Research Points

• 1HGH Fragment 176-191 is the foundational compound that established the principle of functional dissociation within GH structure — the landmark 2001 study (PMID 11713473, J Mol Biol) confirmed that the C-terminal 16 amino acids retain lipolytic activity while the N-terminal region is responsible for IGF-1 induction and anabolic effects. AOD-9604 is a pharmaceutical optimization of this parent fragment, with a single structural modification (N-terminal Tyr) designed to improve stability and bioavailability.
• 2AOD-9604 has the more extensive translational evidence base: its Phase IIb METRO trial generated human pharmacokinetic, safety, and efficacy data in approximately 300 overweight subjects across multiple dose cohorts. The trial did not achieve statistical significance on its primary weight-reduction endpoint, and no further efficacy development was pursued. HGH Fragment 176-191 has not been the subject of published Phase II human trials and remains a preclinical research compound.
• 3Neither compound has demonstrated statistically significant fat-loss effects in controlled human randomised trials. This is a critical translational gap: while animal model data (particularly obese Zucker rat studies for AOD-9604) show dose-dependent lipolytic effects, the human Phase IIb data for AOD-9604 were inconclusive, and HGH Fragment 176-191 lacks human efficacy data entirely. Research citing lipolytic activity for either compound should be interpreted in the context of the relevant model organism.
• 4Both compounds are included on the WADA 2026 Prohibited List (S2) and are classified as Under Review under the FDA 503A compounding framework, restricting patient-specific compounding in the US. Researchers and clinicians working in sport science, doping control, or human pharmacology should verify current regulatory classification before designing protocols involving either compound.
• 5The broader scientific value of both compounds lies in what they revealed about GH receptor structure-activity relationships: by demonstrating that the same parent molecule could be cleaved into a fragment with selective metabolic activity, these peptides established a research paradigm for designing function-selective GH analogues that has informed subsequent adipocyte pharmacology and GH-axis research.

Frequently Asked Questions